Ernexa Therapeutics Inc.
ERNA
$0.2047
-$0.0033-1.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -94.12% | 854.90% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.12% | 854.90% | -- | -- | -- |
| Cost of Revenue | -100.00% | -150.00% | -- | 22.00% | -- |
| Gross Profit | 102.04% | 892.75% | -- | 72.00% | -- |
| SG&A Expenses | -61.87% | -16.50% | 50.42% | 20.13% | 28.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.34% | -22.21% | 21.74% | 9.74% | 4.96% |
| Operating Income | 53.22% | 30.34% | -20.59% | -8.86% | -4.65% |
| Income Before Tax | 6.64% | -374.94% | -22.69% | -22.77% | -38.39% |
| Income Tax Expenses | 375.00% | 250.00% | -25.00% | -20.00% | -110.00% |
| Earnings from Continuing Operations | 6.40% | -375.84% | -22.65% | -22.73% | -37.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.40% | -375.84% | -22.65% | -22.73% | -37.07% |
| EBIT | 53.22% | 30.34% | -20.59% | -8.86% | -4.65% |
| EBITDA | 53.37% | 30.76% | -20.13% | -8.56% | -4.57% |
| EPS Basic | 86.79% | -375.82% | -20.19% | -16.31% | 8.10% |
| Normalized Basic EPS | 84.50% | -2.30% | -31.94% | -17.45% | 16.93% |
| EPS Diluted | 86.79% | -375.82% | -20.19% | -16.31% | 8.10% |
| Normalized Diluted EPS | 84.50% | -2.30% | -31.94% | -17.45% | 16.93% |
| Average Basic Shares Outstanding | 608.63% | 0.00% | 2.02% | 5.52% | 49.08% |
| Average Diluted Shares Outstanding | 608.63% | 0.00% | 2.02% | 5.52% | 49.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.18% | -- | 0.27% |